Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by AngioDynamics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: AngioDynamics’s 10-K, filed July 14, 2026.
- Filed
- Jul 14, 2026, 3:42 PM EDT
- Fiscal year
- FY2026
- Accession
- 0001628280-26-048138
| Line item | Year ended May 31, 2026 | Year ended May 31, 2025 | Year ended May 31, 2024 |
|---|---|---|---|
| Cost of sales (exclusive of intangible amortization) | 145,282 | 134,793 | 149,216 |
| Gross margin | 174,892 | 157,705 | 154,698 |
| Operating expenses | |||
| Research and development | 29,447 | 26,222 | 31,512 |
| Sales and marketing | 113,401 | 103,135 | 102,818 |
| General and administrative | 43,691 | 42,092 | 41,164 |
| Amortization of intangibles | 10,682 | 10,318 | 13,048 |
| Goodwill impairment | — | — | 159,476 |
Item 15. Exhibits, Financial Statement Schedules.
FAQ
- What is AngioDynamics's R&D?
- AngioDynamics (ANGO) reported R&D of $8.18M in Q1 2026.
- How has AngioDynamics's R&D changed year-over-year?
- AngioDynamics's R&D increased by 24.1% year-over-year, from $6.59M to $8.18M.
- What is the long-term trend for AngioDynamics's R&D?
- Over 4 years (2022 to 2026), AngioDynamics's R&D has grown at a -1.1% compound annual growth rate (CAGR), from $30.74M to $29.45M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about AngioDynamics's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude